Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.
Tepes. Marijan M; Krezic. Ivan I; Vranes. Hrvoje H; Smoday. Ivan Maria IM; Kalogjera. Luka L; Zizek. Helena H; Vukovic. Vlasta V; Oroz. Katarina K; Kovac. Katarina Kasnik KK; Madzar. Zrinko Z; Rakic. Mislav M; Miskic. Blazenka B; Sikiric. Suncana S; Barisic. Ivan I; Strbe. Sanja S; Antunovic. Marko M; Novosel. Luka L; Kavelj. Ivana I; Vlainic. Josipa J; Dobric. Ivan I; Staresinic. Mario M; Skrtic. Anita A; Seiwerth. Sven S; Blagaic. Alenka Boban AB; Sikiric. Predrag P
Key Findings
- BPC‑157 (10 µg/kg SC) given 3 min after reperfusion eliminated venous hypertension and aortal hypotension.
- The peptide dramatically reduced organ lesions and oxidative stress markers across brain, heart, liver, kidney and gut.
- It almost completely prevented thrombosis and hemorrhage, restoring normal vein structure and blood flow.
Practical Outcomes
- For biohackers, BPC‑157 shows promise as a rapid‑acting protectant against reperfusion injury, which could be relevant after surgeries, trauma, or intense workouts that cause temporary blood‑flow loss. The rat dose translates to roughly 0.7 mg for a 70‑kg human, but safety and efficacy in people are still unknown, so any use should be experimental and under medical supervision.
Summary
In rats with extreme abdominal pressure and then sudden blood flow restoration (reperfusion), a tiny peptide called BPC‑157 given just minutes after the blood returned stopped dangerous blood‑vessel pressure spikes, organ damage, clotting and bleeding. It quickly repaired the veins and lowered oxidative stress, essentially rescuing the animals from severe injury.
Abstract
Given in reperfusion, the use of stable gastric pentadecapeptide BPC 157 is an effective therapy in rats. It strongly counteracted, as a whole, decompression/reperfusion-induced occlusion/occlusion-like syndrome following the worst circumstances of acute abdominal compartment and intra-abdominal hypertension, grade III and grade IV, as well as compression/ischemia-occlusion/occlusion-like syndrome. Before decompression (calvariectomy, laparotomy), rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii), and severe occlusion/occlusion-like syndrome. Further worsening was caused by reperfusion for 60 min (i) or 30 min (ii/iii). Severe vascular and multiorgan failure (brain, heart, liver, kidney, and gastrointestinal lesions), widespread thrombosis (peripherally and centrally) severe arrhythmias, intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension were aggravated. Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract). Vascular recovery promptly occurred (i.e., congested inferior caval and superior mesenteric veins reversed to the normal vessel presentation, the collapsed azygos vein reversed to a fully functioning state, the inferior caval vein-superior caval vein shunt was recovered, and direct blood delivery returned). BPC 157 therapy almost annihilated thrombosis and hemorrhage (i.e., intracerebral hemorrhage) as proof of the counteracted general stasis and Virchow triad circumstances and reorganized blood flow. In conclusion, decompression/reperfusion-induced occlusion/occlusion-like syndrome counteracted by BPC 157 therapy in rats is likely for translation in patients. It is noteworthy that by rapidly counteracting the reperfusion course, it also reverses previous ischemia-course lesions, thus inducing complete recovery.
Study Information
pubmed
2023
2023-11-02T00:00:00.000Z
10.3390/ph16111554
6
108